115 related articles for article (PubMed ID: 8687522)
1. Insulin and the polycystic ovary syndrome.
Utiger RD
N Engl J Med; 1996 Aug; 335(9):657-8. PubMed ID: 8687522
[No Abstract] [Full Text] [Related]
2. Decreases in ovarian cytochrome P450c17 alpha activity and serum free testosterone after reduction of insulin secretion in polycystic ovary syndrome.
Nestler JE; Jakubowicz DJ
N Engl J Med; 1996 Aug; 335(9):617-23. PubMed ID: 8687515
[TBL] [Abstract][Full Text] [Related]
3. Lean women with polycystic ovary syndrome respond to insulin reduction with decreases in ovarian P450c17 alpha activity and serum androgens.
Nestler JE; Jakubowicz DJ
J Clin Endocrinol Metab; 1997 Dec; 82(12):4075-9. PubMed ID: 9398716
[TBL] [Abstract][Full Text] [Related]
4. Effects of metformin on serum insulin and anti-Mullerian hormone levels and on hyperandrogenism in patients with polycystic ovary syndrome.
Nascimento AD; Silva Lara LA; Japur de Sá Rosa-e-Silva AC; Ferriani RA; Reis RM
Gynecol Endocrinol; 2013 Mar; 29(3):246-9. PubMed ID: 23194004
[TBL] [Abstract][Full Text] [Related]
5. Metabolic features of polycystic ovary syndrome are found in adolescent girls with hyperandrogenism.
Apter D; Bützow T; Laughlin GA; Yen SS
J Clin Endocrinol Metab; 1995 Oct; 80(10):2966-73. PubMed ID: 7559882
[TBL] [Abstract][Full Text] [Related]
6. The metabolic status modulates the effect of metformin on the antimullerian hormone-androgens-insulin interplay in obese women with polycystic ovary syndrome.
Romualdi D; De Cicco S; Tagliaferri V; Proto C; Lanzone A; Guido M
J Clin Endocrinol Metab; 2011 May; 96(5):E821-4. PubMed ID: 21307134
[TBL] [Abstract][Full Text] [Related]
7. Effects of metformin and ethinyl estradiol-cyproterone acetate on clinical, endocrine and metabolic factors in women with polycystic ovary syndrome.
Wu J; Zhu Y; Jiang Y; Cao Y
Gynecol Endocrinol; 2008 Jul; 24(7):392-8. PubMed ID: 18608522
[TBL] [Abstract][Full Text] [Related]
8. The effect of metformin treatment for 2 years without caloric restriction on endocrine and metabolic parameters in women with polycystic ovary syndrome.
Oppelt PG; Mueller A; Jentsch K; Kronawitter D; Reissmann C; Dittrich R; Beckmann MW; Cupisti S
Exp Clin Endocrinol Diabetes; 2010 Oct; 118(9):633-7. PubMed ID: 19998243
[TBL] [Abstract][Full Text] [Related]
9. Obesity, weight loss, and the polycystic ovary syndrome: effect of treatment with diet and orlistat for 24 weeks on insulin resistance and androgen levels.
Panidis D; Farmakiotis D; Rousso D; Kourtis A; Katsikis I; Krassas G
Fertil Steril; 2008 Apr; 89(4):899-906. PubMed ID: 17980364
[TBL] [Abstract][Full Text] [Related]
10. Insulin-like factor 3: a new circulating hormone related to luteinizing hormone-dependent ovarian hyperandrogenism in the polycystic ovary syndrome.
Gambineri A; Patton L; De Iasio R; Palladoro F; Pagotto U; Pasquali R
J Clin Endocrinol Metab; 2007 Jun; 92(6):2066-73. PubMed ID: 17356050
[TBL] [Abstract][Full Text] [Related]
11. Hormonal correlations in the polycystic ovary syndrome.
Messina M; Milani P; Gentile L
Boll Soc Ital Biol Sper; 1986 Jan; 62(1):31-5. PubMed ID: 3087390
[No Abstract] [Full Text] [Related]
12. Effects of metformin therapy on hyperandrogenism in women with polycystic ovarian syndrome.
Kazerooni T; Dehghan-Kooshkghazi M
Gynecol Endocrinol; 2003 Feb; 17(1):51-6. PubMed ID: 12724019
[TBL] [Abstract][Full Text] [Related]
13. Endocrine factors associated with non-alcoholic fatty liver disease in women with polycystic ovary syndrome: do androgens play a role?
Kauffman RP; Baker TE; Baker V; Kauffman MM; Castracane VD
Gynecol Endocrinol; 2010 Jan; 26(1):39-46. PubMed ID: 20001571
[TBL] [Abstract][Full Text] [Related]
14. Metformin treatment reduces ovarian cytochrome P-450c17alpha response to human chorionic gonadotrophin in women with insulin resistance-related polycystic ovary syndrome.
la Marca A; Egbe TO; Morgante G; Paglia T; Cianci A; De Leo V
Hum Reprod; 2000 Jan; 15(1):21-3. PubMed ID: 10611182
[TBL] [Abstract][Full Text] [Related]
15. Angiotensin II type 2 receptor stimulation improves fatty acid ovarian uptake and hyperandrogenemia in an obese rat model of polycystic ovary syndrome.
Leblanc S; Battista MC; Noll C; Hallberg A; Gallo-Payet N; Carpentier AC; Vine DF; Baillargeon JP
Endocrinology; 2014 Sep; 155(9):3684-93. PubMed ID: 24971613
[TBL] [Abstract][Full Text] [Related]
16. [Relations between polycystic ovary and idiopathic hirsutism].
Montesanti F; Rama GP; Francia G; Adami S; Lo Cascio V
G Clin Med; 1988 Mar; 69(3):183-5. PubMed ID: 2971587
[No Abstract] [Full Text] [Related]
17. Typical hormonal profiles are accompanied by increased immunoreactivity of theca folliculi steroid 17 alpha-hydroxylase P450 in polycystic ovary syndrome.
Katulski K; Bornstein S; Figiel M; Wand D; Warenik-Szymankiewicz A; Trzeciak WH
J Endocrinol Invest; 1998 May; 21(5):304-9. PubMed ID: 9648052
[TBL] [Abstract][Full Text] [Related]
18. Detection of functional ovarian hyperandrogenism in women with androgen excess.
Ehrmann DA; Rosenfield RL; Barnes RB; Brigell DF; Sheikh Z
N Engl J Med; 1992 Jul; 327(3):157-62. PubMed ID: 1319000
[TBL] [Abstract][Full Text] [Related]
19. 17 alpha-Hydroxyprogesterone responses to leuprolide and serum androgens in obese women with and without polycystic ovary syndrome offer dietary weight loss.
Jakubowicz DJ; Nestler JE
J Clin Endocrinol Metab; 1997 Feb; 82(2):556-60. PubMed ID: 9024253
[TBL] [Abstract][Full Text] [Related]
20. Polycystic ovaries and obesity.
Messinis IE; Messini CI; Anifandis G; Dafopoulos K
Best Pract Res Clin Obstet Gynaecol; 2015 May; 29(4):479-88. PubMed ID: 25487256
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
